What a complaint about a medicine is supposed to trigger

A complaint is a regulated document

Most writing about consumer complaints is about where to send one. This is about what a rulebook says has to happen at the other end.

The federal manufacturing rules require written procedures describing the handling of all written and oral complaints regarding a drug product, and those procedures have to be followed.

The phrase to notice is "written and oral". A phone call is inside the requirement. So is a message that never uses the word complaint.

Everything that follows hangs off that first sentence. The file, the review, the retention period and the annual look back all exist because a procedure was required first.

Two decisions the procedure has to contain

The same paragraph names two separate assessments, and they send a complaint to two different places.

The first is internal. The procedures have to include provisions for review by the quality control unit of any complaint involving the possible failure of a drug product to meet any of its specifications. For those products, there has to be a determination as to the need for an investigation under the production record review section.

The second is external. The procedures also have to include provisions for review to determine whether the complaint represents a serious and unexpected adverse drug experience. Such an experience has to be reported to the Food and Drug Administration, under the adverse-experience reporting sections named in the same sentence.

So one message can become two things at once. A quality investigation inside the company, and a report to a federal database. The site article on where a side-effect report actually goes covers the second route and what the agency does with it.

What the file has to say

A written record of each complaint is maintained in a file designated for drug product complaints.

The record includes, where known, the name and strength of the drug product, the lot number, the name of the complainant, the nature of the complaint, and the reply to the complainant.

That last field is easy to read past. The regulation contemplates a reply, and it treats the reply as part of the record rather than as a courtesy. A file with no reply in it is visibly incomplete on the rule's own terms.

The first three fields are the ones a reader controls. A complaint that names the product, the strength and the lot number can be matched to a batch. One that names none of them describes an experience rather than a unit.

A decision not to investigate is itself a record, with a name on it

This is the strongest sentence in the section and it covers the outcome nobody writes about.

Where an investigation is conducted, the written record has to include the findings of the investigation and the follow-up.

Where an investigation is not conducted, the written record has to include the reason that an investigation was found not to be necessary, and the name of the responsible person making that determination.

Doing nothing is therefore not a silence. It is a documented decision attached to a named individual, sitting in the same file as the complaint that prompted it.

Where the file lives, and how long

Two provisions decide whether that record can still be read when somebody asks for it.

The complaint file is maintained at the establishment where the drug product was manufactured, processed or packed. It may sit at another facility instead, on condition that the written records are readily available for inspection at that other facility.

Retention runs to the later of two clocks: at least one year after the product's expiration date, or one year after the date the complaint was received. Whichever is longer governs.

The general records section adds the access rule. Records required under the part have to be readily available for authorized inspection during the retention period at the establishment where the activities occurred, and they are subject to photocopying as part of that inspection. Records that can be immediately retrieved from another location by computer count as meeting it.

Complaints get read again once a year

A single complaint is a data point. The rules also require somebody to look at the pile.

Written records have to be maintained so the data in them can be used for evaluating the quality standards of each drug product at least annually. The purpose named is to determine the need for changes in specifications or in manufacturing or control procedures.

The regulation says what that evaluation has to cover. A review of a representative number of batches, whether approved or rejected. And a review of complaints, recalls, returned or salvaged drug products, and investigations, for each drug product.

That is the mechanism by which a pattern becomes visible. Four unrelated messages about the same product are four messages until somebody is required to read them together.

Somebody senior has to be told, in writing

One paragraph pushes the information upward, and its list is broader than complaints.

Procedures have to be established to assure that the responsible officials of the firm are notified in writing of certain events, where those officials are not personally involved or immediately aware of them.

The list names investigations under the complaint section, under the returned drug products section and under the salvaging section. It also names any recalls, any reports of inspectional observations issued by the Food and Drug Administration, and any regulatory actions relating to good manufacturing practices brought by the agency.

The point of the paragraph is that none of those can stay at the level where it happened. Whether that duty reaches a particular business is the scope question below.

The question a complaint raises next: who else received that lot

A complaint about one vial is only useful if the rest of the batch can be found.

Distribution records have to contain the name and strength of the product and a description of the dosage form. They also carry the name and address of the consignee, the date and quantity shipped, and the lot or control number.

A separate section requires written distribution procedures that include a system by which the distribution of each lot can be readily determined, to facilitate its recall if necessary.

Those two provisions are what turn a recall into a list of addresses. The site article on recalls describes how far a notice is designed to travel and who has to be called. These are the records that make the calling possible, and the lot number is the key to both.

What this is not

Three boundaries, because each one is a different question with a different answer.

The regulation quoted here states its own reach. It contains the minimum current good manufacturing practice for preparing drug products for administration to humans or animals. Whether a given compounder is held to it depends on which part of the compounding statute that facility operates under, and that comparison is a separate article on this site.

A complaint to a company is also not a report to a regulator. The two can be triggered by the same message and they go to different places, and the article on where a side-effect report actually goes covers the federal one.

And none of this is a remedy. What a buyer can compel, who may bring an action and what a court may award is the subject of the article on who can actually make a seller answer.

What is worth having in front of you

The fields the regulation names are the ones that make a complaint into a batch-level record rather than an anecdote.

The product name and its strength. The lot number, which is the identifier every other record in this article is keyed to. The nature of the problem, described as an observation rather than as a conclusion.

A reply is the field a reader can ask about directly, since the rule already treats it as part of the record.

And the outcome to expect is not always an investigation. On the rule's own terms, a decision that no investigation was necessary is a legitimate result, and it comes with a written reason and a named person attached to it.

Sources

Each document below is named as it names itself, with the date printed on that document rather than the day it was read.

1. Title 21 Code of Federal Regulations Section 211.198, Complaint files, read in full including the written and oral complaint procedure, the quality control unit review, the reportable adverse drug experience determination, the record contents at paragraph (b)(1) and the written reason required at paragraph (b)(3) where no investigation is conducted — Office of the Federal Register, Electronic Code of Federal Regulations, September 2026
2. Title 21 Code of Federal Regulations Section 211.180, General requirements, including the record retention periods, the availability of records for authorized inspection at paragraph (c), the annual evaluation at paragraph (e) and the written notification of responsible officials at paragraph (f) — Office of the Federal Register, Electronic Code of Federal Regulations, September 2026
3. Title 21 Code of Federal Regulations Section 211.196, Distribution records, requiring the product name and strength, the dosage form, the name and address of the consignee, the date and quantity shipped and the lot or control number — Office of the Federal Register, Electronic Code of Federal Regulations, September 2026
4. Title 21 Code of Federal Regulations Section 211.150, Distribution procedures, whose paragraph (b) requires a system by which the distribution of each lot can be readily determined to facilitate its recall — Office of the Federal Register, Electronic Code of Federal Regulations, September 2026
5. Title 21 Code of Federal Regulations Section 211.1, Scope, stating that the part contains the minimum current good manufacturing practice for preparation of drug products for administration to humans or animals — Office of the Federal Register, Electronic Code of Federal Regulations, September 2026